Our CEO Shares Insights on the Results from ongoing PDC-LUNG-101 clinical trial in e-Magazine PharmaShots
Eric Halioua, President & CEO at PDC*line Pharma Shares Insights on the Results from ongoing PDC-LUNG-101 clinical trial
We are very pleased to announce that a new article, following an interview of our CEO Eric Halioua, has been published in the web magazine PharmaShots.com . In this article, Eric Halioua shared the results from the first immunological results of its PDC-LUNG-101 ongoing Phase I/II trial with PDC*lung01 which is the company’s cancer vaccine candidate for Non-Small Cell Lung Cancer. The results were presented at ESMO-IO 2022 elaborating on the safety, tolerability, immunogenicity, and preliminary clinical activity of the drug candidate. The interview shows PDC*line’s vision to develop an innovative class of active immunotherapies for cancers, based on a GMP-grade allogeneic therapeutic cell line of Plasmacytoid Dendritic Cells (PDC*line).
Full article is available by clicking in link below:
ABOUT PHARMASHOTS
PharmaShots brings curated, summarized, authentic and insightful life science and pharmaceutical global news for their readers
PharmaShots offers their reader critical insights and exclusive anecdotes on the technologies, products, deals, funding, companies, and products influencing paradigm shifts in the life science industry affecting human health
PharmaShots brings news from boardrooms, labs, sales teams, hospitals and other KOL and experts to your inbox
